Tags

Type your tag names separated by a space and hit enter

Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
Diabetes Metab Syndr. 2016 Apr-Jun; 10(2):88-91.DM

Abstract

AIM

The study was aimed to investigate the effect of voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India.

PARTICIPANTS AND METHODS

A retrospective study included 77 participants (BMI≥25kg/m(2); HbA1c level>8% and<9.5%) with overweight/obese T2DM. These participants were treated with either voglibose or acarbose. Glycemic parameters (fasting blood glucose and glycated hemoglobin [HbA1c]), bodyweight, BMI and lipid parameters were evaluated at baseline, 3-month, 6-month and 9-month of treatment. Adverse events were also captured at respective time points.

RESULTS

Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P<0.05 and 9 months; P<0.01) whereas acarbose showed significant reduction with longer duration of treatment (9 months; P<0.05) when compared with baseline. Moreover, both treatment groups were reported with reduction in BMI. Further, significant improvement in lipid parameters except LDL and HDL were observed in both treatment groups when compared with baseline. None of participant was discontinued due to side effects of the treatment. In addition, the frequency of hypoglycemia was decreased in both treatment groups.

CONCLUSION

Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.

Authors+Show Affiliations

Department of Research, DiaCare - An Advance Diabetes Care Centre, Ahmedabad, India; Faculty of Pharmaceutical sciences, Pacific University, Udaipur, India. Electronic address: talaviyapraful@gmail.com.Department of Research, DiaCare - An Advance Diabetes Care Centre, Ahmedabad, India.Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad, India.C. T. Institute of Pharmaceutical Sciences, Jalandhar, India.Joshi Clinics, Mumbai, India.Department of Pharmacology, Institute of Pharmacy - Nirma University, Ahmedabad, India.Lecturer, Rai University, Ahmedabad, India.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

26777258

Citation

Talaviya, Praful A., et al. "Retrospective Comparison of Voglibose or Acarbose as an Add-on Therapy to Sulfonylureas in Western Indian Patients With Uncontrolled Overweight/obese Type 2 Diabetes." Diabetes & Metabolic Syndrome, vol. 10, no. 2, 2016, pp. 88-91.
Talaviya PA, Saboo BD, Dodiya HG, et al. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes. Diabetes Metab Syndr. 2016;10(2):88-91.
Talaviya, P. A., Saboo, B. D., Dodiya, H. G., Rao, S. K., Joshi, S. R., Modh, V. B., & Ghadiya, S. V. (2016). Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes. Diabetes & Metabolic Syndrome, 10(2), 88-91. https://doi.org/10.1016/j.dsx.2015.09.021
Talaviya PA, et al. Retrospective Comparison of Voglibose or Acarbose as an Add-on Therapy to Sulfonylureas in Western Indian Patients With Uncontrolled Overweight/obese Type 2 Diabetes. Diabetes Metab Syndr. 2016 Apr-Jun;10(2):88-91. PubMed PMID: 26777258.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes. AU - Talaviya,Praful A, AU - Saboo,Banshi D, AU - Dodiya,Hardik G, AU - Rao,Shaival K, AU - Joshi,Shashank R, AU - Modh,Vipul B, AU - Ghadiya,Sneha V, Y1 - 2015/11/25/ PY - 2015/07/24/received PY - 2015/09/27/accepted PY - 2016/1/19/entrez PY - 2016/1/19/pubmed PY - 2016/1/19/medline KW - Hb1Ac KW - Hypoglycemia KW - Obese/overweight T2DM KW - Sulfonylureas SP - 88 EP - 91 JF - Diabetes & metabolic syndrome JO - Diabetes Metab Syndr VL - 10 IS - 2 N2 - AIM: The study was aimed to investigate the effect of voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. PARTICIPANTS AND METHODS: A retrospective study included 77 participants (BMI≥25kg/m(2); HbA1c level>8% and<9.5%) with overweight/obese T2DM. These participants were treated with either voglibose or acarbose. Glycemic parameters (fasting blood glucose and glycated hemoglobin [HbA1c]), bodyweight, BMI and lipid parameters were evaluated at baseline, 3-month, 6-month and 9-month of treatment. Adverse events were also captured at respective time points. RESULTS: Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P<0.05 and 9 months; P<0.01) whereas acarbose showed significant reduction with longer duration of treatment (9 months; P<0.05) when compared with baseline. Moreover, both treatment groups were reported with reduction in BMI. Further, significant improvement in lipid parameters except LDL and HDL were observed in both treatment groups when compared with baseline. None of participant was discontinued due to side effects of the treatment. In addition, the frequency of hypoglycemia was decreased in both treatment groups. CONCLUSION: Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile. SN - 1878-0334 UR - https://www.unboundmedicine.com/medline/citation/26777258/Retrospective_comparison_of_voglibose_or_acarbose_as_an_add_on_therapy_to_sulfonylureas_in_Western_Indian_patients_with_uncontrolled_overweight/obese_type_2_diabetes_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1871-4021(15)30015-1 DB - PRIME DP - Unbound Medicine ER -